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Objective—A major barrier to genetic studies of OA is the need to obtain large numbers of 
individuals with standardized radiographic evaluations for OA. To address this gap, we performed 
a genome-wide association study (GWAS) of radiographically-defined tibiofemoral knee OA in 
3,898 cases and 3,168 controls from four well-characterized North American cohorts, and 
replication analysis of published OA loci.
Methods—We performed meta-analysis using a two-stage design. Stage 1 (discovery) consisted 
of a GWAS meta-analysis of radiographic knee OA carried out in the Osteoarthritis Initiative and 
the Johnston County Osteoarthritis Project. Knee OA was defined as definitive osteophytes and 
possible joint space narrowing or total joint replacement in one or both knees. Stage 2 (validation) 
was performed in the Multicenter Osteoarthritis Study and Genetics of Osteoarthritis Study. We 
genotyped lead meta-analysis variants (P-value<1×10−4) from Stage 1 and tested the association 
between these variants and knee OA. We then combined results from all cohorts in a meta-
analysis.
Results—Lead variants from Stage 1, representing 49 unique loci, were analyzed in Stage 2; 
none met genome-wide significance in the combined analysis of Stage 1 and 2. We validated one 
locus with nominal significance (P-value<0.05), which was also our top finding in the combined 
meta-analysis: rs4867568 (LSP1P3, OR[95% CI]=0.84[0.79–0.91], P-value=3.02×10−6). We 
observed nominally significant associations (P-value<0.05) with two published OA loci: rs143383 
(GDF5, OR[95% CI]=1.12[1.04–1.21], P-value=2.13×10−3) and rs1558902 (FTO, OR[95% 
CI]=1.10[1.02–1.18], P-value=0.01).
Conclusion—These findings provide suggestive evidence for a novel knee OA locus and 
confirm previously published associations in GDF5 and FTO.
It has long been recognized that there is a strong genetic component to osteoarthritis (OA) as 
evidenced by the clustering of hand osteoarthritis within families (1). More recent twin 
studies have estimated that the heritability of hip and knee OA is 60% for hip OA (2) and 
39% for knee OA (3). These estimates suggest that genetic factors may play a large role in 
the development of OA, although this may differ by joint site (4). Large-scale genome-wide 
association studies (GWAS) of hand, hip, and knee osteoarthritis have been conducted in 
European Caucasians, providing a dozen genome-wide significant loci that include 
ALDH1A2 for hand OA (5), DOT1L, NCOA3, ASTN2, FILIP1/SENP6, KLHDC5/PTHLH, 
and CHST11 for hip OA (6–9), and GDF5, chromosome 7q22, and MCF2L for knee OA 
(10–13). Variants in two other genes, GLT8D1 and GNL3, have been associated at genome-
wide levels of significance with total joint replacement (9).
Despite numerous efforts to identify genetic factors associated with OA, robust replication 
of findings has been difficult. This is likely due to the highly heterogeneous nature and 
phenotype specificity of OA, as well as potentially different environmental effects on 
weight-bearing and non-weight-bearing joint sites (14). The genetic architecture of OA 
likely involves many loci, each having small effect sizes. Nevertheless, identifying even 
small effect size loci may provide insights into aspects of etiology and pathogenesis of OA 
that in some cases may suggest targets for prevention and treatment. A major barrier to 
large-scale genetic studies of OA has been the difficulty in obtaining large numbers of 
subjects who have undergone rigorous phenotyping using standardized evaluation. To 
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address this gap, we performed a two-stage genome-wide association study (GWAS) of 
radiographically-defined tibiofemoral knee OA in 3,898 cases and 3,168 controls from four 
well-characterized North American OA cohorts. We also evaluated evidence for the 
association of knee OA with previously published OA loci.
PATIENTS AND METHODS
We conducted a GWAS of radiographic tibiofemoral knee OA in Caucasian subjects using a 
two-stage design. Stage 1 (discovery) consisted of a GWAS meta-analysis carried out in two 
independent populations: the Osteoarthritis Initiative (OAI) and the Johnston County 
Osteoarthritis Project (JoCo). In Stage 2 (validation), lead SNPs from the most significantly 
associated loci identified from the meta-analysis were genotyped and tested for association 
in two independent cohorts: the Multicenter Osteoarthritis Study (MOST) and The Genetics 
of Osteoarthritis (GO) study. Finally, we conducted a full meta-analysis of the lead SNPs by 
combining study results from all four cohorts. Knee OA was evaluated with fixed-flexion 
posteroanterior (PA) radiographs. Definitive knee OA was defined as having definite 
osteophytes and possible joint space narrowing (Kellgren-Lawrence [KL] grade ≥ 2) or total 
joint replacement in one or both knees. We defined controls as having in both knees no or 
doubtful evidence for OA (KL grade = 0 or 1) at all available time points. The same 
definition for cases and controls were used in Stage 1 and Stage 2 analyses.
Stage 1 cohorts included 2,672 cases (2,014 from OAI and 658 from JoCo) and 1,776 
controls (953 from OAI and 823 from JoCo). Discovery loci that met suggestive evidence 
(P-value < 1×10−4) in Stage 1 were brought forward for de novo genotyping in Stage 2 
cohorts. Stage 2 cohorts included 1,226 cases (709 from MOST and 517 from GO) and 
1,392 controls (405 from MOST and 987 from GO). In total, there were 3,898 cases and 
3,168 controls. We considered associations to be genome-wide significant if they reached 5 
× 10−8 in the combined meta-analysis of Stage 1 and Stage 2 results.
Discovery cohorts
The Osteoarthritis Initiative (OAI) is a prospective longitudinal study designed to identify 
risk factors for the incidence and progression of symptomatic tibiofemoral knee OA. A total 
of 4,796 men and women of any race/ethnicity aged 45 – 79 years were enrolled into pre-
defined progression or incidence subcohorts (15). Briefly, the progression subcohort 
included individuals who had symptomatic radiographic knee OA while the incidence 
subcohort included individuals who were considered to be at increased risk for developing 
symptomatic radiographic knee OA based on weight, knee symptoms, history of knee 
injuries/surgeries, family history of knee replacement and hand OA. Participants were 
recruited at four different clinical sites: 1) Brown University (Providence, RI); 2) The Ohio 
State University (Columbus, OH); 3) University of Maryland and The Johns Hopkins 
University (Baltimore, MD); and 4) University of Pittsburgh (Pittsburgh, PA). Details of the 
study protocol, including recruitment procedures and eligibility criteria are available on the 
OAI web site (http://oai.epi-ucsf.org/datarelease/docs/StudyDesignProtocol.pdf).
A total of 4,492 subjects aged 45–79 years received bilateral PA weight-bearing fixed-
flexion knee radiograph at baseline between 2004 and 2006 and were invited back to assess 
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incidence or progression of OA annually for up to 96 months. We restricted analyses to 
centrally read annual assessments up to 48 months. Central image assessment data releases 
were version 0.5 for baseline, 1.5 for 12-month, 3.4 for 24-month, 5.4 for 36-month, and 6.2 
for 48-month visits. For this study, radiographs obtained at baseline were used to define OA 
cases; baseline and follow-up radiographs were used to define controls.
The Johnston County Osteoarthritis Project (JoCo) is an ongoing, community-based study of 
the occurrence of knee and hip OA in African American and Caucasian residents, aged 45 
years and above, in a rural county in North Carolina. A detailed description of participant 
recruitment has been reported (16). Briefly, participants were recruited by probability 
sampling, with oversampling of African Americans. A total of 3,068 individuals were 
recruited at baseline. Similar to the OAI, cases in JoCo were defined at baseline (1991–
1998), and controls were required to be OA-free at baseline and up to two subsequent 
follow-up exams (1999–2004 and 2006–2010). The current analysis includes 1,481 
Caucasian participants with genotype data and radiographic information obtained from 
weight-bearing anteroposterior (AP) extended radiographs at baseline and fixed-flexion PA 
radiographs at follow-up. There is substantial agreement by KL grade between AP extended 
and PA fixed-flexion radiographs (17).
Validation cohorts
The Multicenter Osteoarthritis Study (MOST) is a longitudinal, prospective, observational 
study of knee OA in older individuals from the general population who either have OA or 
are at increased risk for developing knee OA based on weight, knee symptoms, or history of 
knee injuries/surgeries (18). Additional information regarding recruitment and study 
protocols are available on the MOST website (http://most.ucsf.edu/default.asp). A total of 
3,026 participants were enrolled. Baseline examinations began in 2003 and follow-up visits 
were attempted at 15, 30, 60, and 84 months after the initial visit to collect clinical 
measurements and radiological data. Similar to the OAI and JoCo, cases were defined at 
baseline and controls were required to be OA-free at baseline and subsequent follow-up 
visits up to 60 months.
The Genetics of Osteoarthritis (GO) Study is a case-control based genetic association study 
of OA. The goal of this study was to identify genetic variations associated with OA, with 
careful attention to rigorous phenotyping of controls in the same manner as the cases (19). 
The GO study recruited approximately 1,000 OA participants with hand osteoarthritis with 
or without OA in knees, hips, and lumbosacral spine in the Caucasian population and 1,000 
unaffected controls with similar age, gender and ethnicity.
Genotyping
The OAI was genotyped on the Illumina Omni-Quad 2.5M array at the Translational 
Genomics Research Institute (Phoenix, AZ) and the JoCo study was genotyped on the 
Illumina Infinium 1M-Duo bead array at Expression Analysis (Morrisville, NC). Genotypes 
for both studies were called using the Illumina BeadStudio software. The total number of 
genotyped SNPs was 2,440,283 in OAI and 1,199,187 in JoCo.
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Samples that had call rates across all SNPs of <95% were removed (185 samples in OAI and 
13 samples in JoCo). We additionally excluded from analysis potentially problematic 
samples based on 1) apparent mismatches between self-reported and genetically determined 
gender or 2) detection of second degree or higher relationships with other samples (56 
samples in OAI and 40 samples in JoCo). An additional 34 OAI samples were excluded in 
whom we detected large chromosomal abnormalities using Log R Ratio (LRR) and B Allele 
Frequency (BAF), as described by others (20–22). Genotypes for both cohorts were imputed 
to the 1000 genomes CEU reference panel (June 2011 release) using the Minimac software 
program (http://genome.sph.umich.edu/wiki/Minimac), resulting in a total of 8,248,570 and 
8,349,255 imputed SNPs in the OAI and JoCo, respectively, available for analyses after 
removal of SNPs with low minor allele frequencies (<1%) and poor imputation quality 
scores (<0.3).
Genotyping for Stage 2 was performed at the Translational Genomics Research Institute 
(Phoenix, AZ) on a customized Illumina array, which was designed to capture 49 top loci (P-
value ≤ 1×10−4) identified in Stage 1 and previously reported OA variants from large-scale 
genome-wide association studies (9, 23). We removed SNPs with call rates <99% and 
samples with genotyping rates <97%. Furthermore, SNPs with extreme deviation from 
Hardy-Weinberg equilibrium (P-value < 1×10−7) and minor allele frequencies <1% were 
removed.
Statistical analysis
Association analysis for the OAI and JoCo were conducted using PLINK and ProbABEL, 
respectively, with adjustment for baseline age, sex, study site, and principal components 
(PCs). PCs estimated from the genetic data were included to account for unobserved 
population sub-structure and were derived from the genome-wide SNPs, following LD 
pruning and removal of SNPs with minor allele frequencies <5%. Only SNPs that had minor 
allele frequencies >1% and imputation quality score >0.3 were included in Stage 1 analyses. 
Inverse variance fixed-effects meta-analysis was carried out using METAL (24), which 
weights the contribution of both studies by the observed standard error. Heterogeneity 
between studies was assessed using Cochran’s Q statistic. We performed a meta-analysis of 
genome-wide association results from the OAI and JoCo and brought forward the most 
strongly associated loci (P-value < 10−4) for de novo genotyping on a customized array in 
two independent cohorts, MOST and GO. These top loci were pruned so that only the most 
significant SNP in a pair of SNPs in high linkage disequilibrium (LD), r2 > 0.8, was 
selected. If the selected SNP could not be genotyped, then the second most significant SNP 
was selected or a proxy in high LD, r2 > 0.8, was chosen as a tag SNP. We also performed 
association analysis of previously reported OA loci including three knee OA loci (10–13) 
and eight loci from the arcOGEN (Arthritis Research Council Osteoarthritis Genetics) study 
(9). After validation analyses of top loci and previously reported loci in Stage 2, we then 
combined results from Stage 1 and Stage 2 in a meta-analysis to determine whether any loci 
from Stage 1 could be elevated to genome-wide significance with the addition of data from 
Stage 2. We also performed secondary analyses additionally adjusting for body mass index 
(BMI) and history of knee injury or surgery.
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We estimated that our two-stage design totaling 3,898 cases and 3,168 controls provided 
80% power to detect odds ratios ranging from 1.24 – 1.39 for OA-associated SNPs at an 
alpha = 5×10−8 (i.e., conventional thresholds for genome-wide statistical significance) 
across a range of allele frequencies, and odds ratios ranging from 1.13 – 1.24 for OA-
associated SNPs at an alpha = 1×10−5.
RESULTS
Our sample included 2,672 cases and 1,776 controls in Stage 1 (discovery), and 1,226 cases 
and 1,392 controls in Stage 2 (validation); all were self-reported Caucasians. In total, there 
were 3,898 cases and 3,168 controls in the full meta-analysis across Stages 1 and 2. Clinical 
characteristics of Stage 1 (OAI and JoCo) and Stage 2 (MOST and GO) samples are 
provided in Table 1. OA cases had a mean age of 63–64 years in OAI, JoCo, and MOST, and 
72 years in GO. Cases were more likely than controls to be women in both the OAI (56% vs. 
54%) and MOST (60% vs. 54%). The proportion of women was similar between cases and 
controls in JoCo (61%) and GO (70%). Across all studies, cases had a higher body mass 
index than controls (OAI: 29.0 vs. 27.0 kg/m2, JoCo: 30.2 vs. 28.0 kg/m2, MOST: 31.4 vs. 
28.4 kg/m2, GO: 28.9 vs. 26.9 kg/m2). Also, cases in all studies had a higher proportion of 
individuals who had a history of knee injury (OAI: 50.8% vs. 38.5%, JoCo: 27.2% vs 
15.9%, MOST: 53.5% vs. 36.7%, GO: 14.3% vs. 6.0%) or knee surgery (OAI: 32.2% vs. 
12.2%, JoCo: 15.4% vs 2.6%, MOST: 35.0% vs. 11.1%, GO: 20.9% vs. 4.6%).
Stage 1 (discovery)
Results of Stage 1 genome-wide association meta-analysis of knee OA in OAI and JoCo are 
summarized in the Manhattan plot shown in Figure 1. No SNP achieved genome-wide 
significance (i.e., 5×10−8). The most significant finding (rs274508, OR [95% CI]=0.77 
[0.70–0.85], P-value=2.00×10−7) was located within an intergenic region on chromosome 11 
between ZBED5 (zinc finger BED domain-containing protein 5) and GALNT18 
(polypeptide N-Acetylgalactosaminyltransferase 18). The minor allele frequency at this SNP 
was 0.32.
Following genome-wide association analyses in the discovery set, we identified 823 SNPs 
associated with knee OA at a P-value threshold ≤ 1×10−4. We used linkage disequilibrium 
pruning (removing SNPs with r2 < 0.80 to an already captured SNP) to reduce this number 
to 49 uncorrelated SNPs. We carried forward these 49 unique loci for de novo genotyping in 
MOST and GO.
Stage 2 (validation)
Of the 49 SNPs tested, five were associated at nominal levels of statistical significance (P-
value < 0.05) in Stage 2, including rs4867568 near LSP1P3 (OR [95% CI]=0.88 [0.78–
0.99]), rs1026407 in COL27A1 (OR [95% CI]=1.57 [1.09–2.27]), rs1026407 in UBE2E1 
(OR [95% CI]=1.16 [1.01–1.32]), rs1628543 near TBK1/RASSF3 (OR [95% 
CI]=1.13[1.00–1.27]), and rs6892607 near FAM173B (OR [95% CI]=0.80 [0.68–0.94]) 
(Table 2). However, only one of these SNPs, rs4867568, was validated in the same direction 
of effect as in Stage 1, yielding a combined Stage 1 and Stage 2 meta-analysis P-value of 
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3.02×10−6 (OR [95% CI]=0.84 [0.79–0.91]). None of the nominally validated SNPs (nor any 
of the other SNPs from Stage 1) achieved genome-wide levels of significance in the 
combined Stage 1 and 2 meta-analysis.
In secondary analyses, we included additional adjustments for BMI and history of knee 
injury or surgery, which resulted in no to slight attenuation of top associations (P-value < 
1×10−5) in the combined Stage 1 and 2 meta-analysis (Table 3). There were four loci that 
reached suggestive significance (P-value < 1×10−5) only after adjusting for BMI (rs7079380 
and rs11258527 in FRMD4A) and history of knee injury/surgery (rs6963954 in NOD1 and 
rs974515 near CRBN/LRRN1) (Table 3).
Replication of previously reported OA loci
We also tested associations between previously reported OA SNPs that were genome-wide 
significant or replicated across several studies (9–13), which were mostly conducted in 
European cohorts. We detected nominally significant associations (P-value < 0.05) with 
three of the 11 previously reported OA SNPs: rs143383 near GDF5 (OR [95% CI]=1.12 
[1.04–1.21], P-value=2.13×10−3); rs835487 near CHST11 (OR [95% CI]=0.93 [0.85–0.99], 
P-value=0.03); and rs8044769 near FTO (OR [95% CI]=1.10 [1.03–1.19], P-
value=6.13×10−3). Associations observed for GDF5 and FTO, but not CHST11, were 
directionally consistent with previously reported effects (Table 4). Notably, the odds ratios at 
all loci estimated in our study were smaller than the published results.
DISCUSSION
We performed the largest and most comprehensive GWAS of radiographic tibiofemoral knee 
OA yet to be carried out in North American Caucasians, incorporating four independent 
cohorts and a two-stage design. Our study provides suggestive evidence for a novel knee OA 
locus on chromosome 5p13 near LSP1P3 (lymphocyte-specific protein 1 pseudogene 3), 
which has not been identified by any other GWAS to date. In contrast to previously 
published large-scale OA GWAS, which largely included cases that underwent total joint 
replacement, our study focused particularly on tibiofemoral knee OA cases defined 
radiographically by definite osteophytes and possible joint space narrowing; less than 5% 
had total joint replacements. We also provide modest replication for two previously reported 
OA loci, including GDF5 and FTO. Even with a large sample size of 3,898 cases, we did not 
identify any loci at genome-wide levels of significance and replicated only two loci at 
nominal levels of significance. These findings highlight the polygenic nature of knee OA 
and the need for even larger studies to achieve sufficient power to detect small effect sizes.
Similar to other complex diseases, the genetic architecture of OA is characterized by many 
common genetic variants (minor allele frequencies greater than 5%) with small effect sizes. 
So far, only a dozen genome-wide significant loci have been identified for knee and hip OA 
in European Caucasians, ranging in effect sizes from 1.12 to 1.28 (25). The largest GWAS of 
OA to date was conducted by the arcOGEN (Arthritis Research Council Osteoarthritis 
Genetics) study in the United Kingdom, which included 7,410 cases and about 11,000 
population controls (9). The arcOGEN study identified five novel loci at genome-wide 
significance (GLT8D1/GNL3, ASTN2, FILIP1/SENP6, KLHDC5/PTHLH, and CHST11) 
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and three novel loci at near genome-wide significance (TP63, FTO, and SUPT3H/CDC5L). 
Of these eight loci, we replicated only one, the FTO locus, despite having enough statistical 
power to detect odds ratios greater than 1.10 at nominal significance. One possible 
explanation for this is that some of the OA-associated loci reported in arcOGEN were 
specific to hip OA and some were only significant in sub-analyses restricted to men or 
women. We also used a slightly different, less severe, radiographic tibiofemoral knee OA 
phenotype. Fewer than 5% of our cases had total knee replacements while the majority of 
arcOGEN cases (~80%) had total hip and/or knee replacements.
One of the major challenges facing genetic studies of knee OA is the high degree of 
phenotype heterogeneity that exists due to differences in phenotype definition. Recent efforts 
have focused on standardizing phenotype definitions across genetic studies of OA so as to 
reduce phenotype heterogeneity and facilitate replication (14). Both symptomatic and 
radiographic definitions are used in genetic studies of OA and may yield different 
associations. Furthermore, even within the commonly used KL grading system for 
radiographic OA, KL grades may be interpreted differently across cohorts. For example, in 
the TREAT-OA (Translational Research in Europe Applied Technologies for Osteoarthritis) 
consortium, there were at least three different interpretations of KL grade 2, including “one 
definite osteophyte”, “definite osteophytes”, and “definite osteophytes with possible joint 
space narrowing” (14). In our study of North American OA cohorts, radiographic knee OA 
was defined as definite osteophytes with possible joint space narrowing at the tibiofemoral 
joint, the classic interpretation of KL grade 2 knee OA (26). This definition was 
standardized across all cohorts to limit phenotype heterogeneity and improve power to detect 
genetic associations.
Another source of phenotype heterogeneity may be confounding by risk factors that 
contribute to OA liability. A significant proportion of cases and controls in this analysis had 
a history of previous knee injury, one of the primary risk factors for knee OA aside from 
advanced age, overweight, obesity, and female gender (27). There are several models by 
which knee trauma may affect genetic associations. One model may consider knee trauma as 
an independent risk factor for OA that does not operate through genetics and is itself 
sufficient for putting one on the path to OA. Under this model the most appropriate analysis 
would be not to adjust for history of knee trauma, as this assumes the impact of OA 
susceptibility loci would be identical in those with and without knee injury, but rather to 
exclude those with knee injury. A second model is that OA risk alleles influence OA risk 
independently of prior knee trauma. Under this model, adjustment for prior knee injury 
should not alter the effects of OA risk loci on OA risk. Yet a third model is that knee trauma 
provides a permissive milieu in which OA risk alleles are more likely to be expressed. Under 
this model, a follow-up analysis that adjusts for prior knee injury on OA risk should 
attenuate the effects of these loci. Associations with our top meta-analysis finding and 
replicated findings in GDF5 and FTO remained largely unchanged after adjusting for knee 
trauma, suggesting that these loci operate independently of prior knee trauma. While history 
of knee injury or surgery may not necessarily lead to post-traumatic OA, our findings are 
consistent with other reports that the genetic contribution to post-traumatic and non-
traumatic knee OA may be similar (28).
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The strength of our GWAS is in fact the careful phenotyping of all subjects using 
standardized radiography methods across all four meta-analysis cohorts and the availability 
of longitudinal data to radiographically confirm the absence of knee OA in controls at all 
follow-up exams over an average of five years. However, the time between the initiating 
event and onset of knee OA is often much longer. Controls were younger than cases and it 
may be only a matter of time before they develop knee OA. It is therefore possible that 
individuals classified as controls may eventually become cases at a later time point than we 
were able to capture from existing longitudinal data. This is especially relevant to OAI and 
MOST studies that ascertained participants who either have or are at high risk for 
symptomatic OA. Controls from OAI and MOST may be more likely to be misclassified as 
disease-free than controls from JoCo and GO, resulting in less power to detect significant 
associations. Including older, disease-free controls without predisposing risk factors would 
be ideal and help reduce misclassification bias.
While one of the strengths of our analysis was the standardized radiographic assessment of 
knee OA across all four studies, the major limitation was the small sample size. Even with 
nearly 4,000 cases, we were powered to detect odds ratios of only 1.24 to 1.39 at genome-
wide levels of significance. Odds ratios for prior loci associated with knee OA range from 
1.12 to 1.28. Since genome-wide genotyping was available for OAI and JoCo studies only, 
we were limited to a two-stage GWAS that has less power than a single-stage GWAS with 
the same number of samples. Also, Stage 2 was smaller in sample size than Stage 1 and 
would have less power to detect significant associations, further hampering replication. 
Additional large replication samples will be needed to increase sample size and power to 
elevate small-effect loci from suggestive to genome-wide significance.
In summary, we conducted the largest GWAS study of tibiofemoral knee OA in North 
American Caucasian OA cohorts to date based on standardized radiographic phenotypes. 
Our study validated two previously reported OA-associated loci in GDF5 and FTO, the latter 
likely exerting its effects through body mass index (29). The small effect sizes identified in 
this study are in line with the highly polygenic nature of knee OA, and even larger scale 
GWAS meta-analysis of knee OA will be needed to provide genome-wide statistical 
evidence.
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Figure 1. 
Manhattan plot for Stage 1 (discovery) GWAS. The red horizontal line depicts genome-wide 
significance (P-value < 5×10−8). The blue horizontal line depicts suggestive significance (P-
value < 1×10−5).
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